Fill in some text
Amgen Inc said on Thursday it would purchase ChemoCentryx Inc for $3.7 billion to get to the organization's enemy of aggravation drug.
ChemoCentryx makes Tavneos, a medication endorsed to treat patients with an uncommon type of vein irritation. The treatment got deals of $5.4 million in the principal full quarter since its send off.
Amgen said it will pay $52 a portion of ChemoCentryx, over two times Wednesday's end cost of $24.11 for the San Carlos, Calif., organization.
The arrangement, scheduled to shut before the year's over, supports Amgen's pipeline of disease and resistant medications with the expansion of ChemoCentryx's Tavneos, which last year won U.S. Food and Drug Administration endorsement for an interesting invulnerable framework illness.